Table 4.
Effectiveness of the interventions in the subgroup with uncontrolled T2DM at baseline
|
PNT n: 27 (39%) Mean treatment duration (weeks): 6.7 ± 1.7 |
CT n: 21 (37%) Mean treatment duration (weeks): 12.5 ± 6.8 |
|||||
|---|---|---|---|---|---|---|
| Before treatment | End of treatment | One year | Before treatment | End of treatment | One year Mean ± SD | |
| Weight (kg) | 120.2 ± 20 | 113.1 ± 18.7** | 113.2 ± 22.1*** | 99.7 ± 18.9 | 98.6 ± 18.3 | 100.4 ± 18.5 |
| BMI (kg/m2) | 43.4 ± 5.4 | 40.8 ± 4.8*** | 40.6 ± 6.1*** | 36.5 ± 5.1 | 35.9 ± 4.7 | 36.5 ± 4.7 |
| Insulin use | 100% | 89% | – | 90% | 90% | – |
| TDD‡ (UI) | 66 ± 33 | 37 ± 25** | 48 ± 32** | 51 ± 36 | 47 ± 32 | 55 ± 33 |
| Fasting glucose (mg/dl) | 203 ± 50 | 159 ± 54** | – | 219 ± 80 | 157 ± 42* | – |
| HbA1c (%) | 9.3 ± 1.6 | 7.7 ± 1.5** | 8.3 ± 1.5* | 9.1 ± 1.5 | 8.0 ± 0.9* | 8.5 ± 0.8 |
PNT psycho-nutritional treatment, CT Conventional treatment
Data are presented as Means ± SD. Uncontrolled T2DM is defined with a HbA1c values > 7,5%; ‡Total Daily Dose. *p < 0.05 compared to baseline; **p < 0.01 compared to baseline; ***p < 0.001 compared to baseline